|
注册号: Registration number: |
ChiCTR2000038537 |
|
最近更新日期: Date of Last Refreshed on: |
2020-09-23 05:26:10 |
|
注册时间: Date of Registration: |
2020-09-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
Large vessel thrombosis in patients with COVID-19 |
|
Public title: |
Large vessel thrombosis in patients with COVID-19 |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
A single center prospective case series study of large vessel thrombosis due to COVID-19 |
|
Scientific title: |
A single center prospective case series study of large vessel thrombosis due to COVID-19 |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
Hawbash Mohammed-Amin Rahim |
研究负责人: |
Fahmi Hussein Kakamad |
|
Applicant: |
Hawbash Mohammed-Amin Rahim |
Study leader: |
Fahmi Hussein Kakamad |
|
申请注册联系人电话: Applicant telephone: |
+96 475 03282480 |
研究负责人电话:
Study leader's |
+96 477 25268326 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hawbash.mhamad@kscien.org |
研究负责人电子邮件: Study leader's E-mail: |
fahmi.hussein@univsul.edu.iq |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
Hawari Shar Str, Sulaimani, Kurdistan, Iraq |
研究负责人通讯地址: |
Shari Pzishkan, Sulaimani, Kurdistan, Iraq |
|
Applicant address: |
Hawari Shar Str, Sulaimani, Kurdistan, Iraq |
Study leader's address: |
Shari Pzishkan, Sulaimani, Kurdistan, Iraq |
|
申请注册联系人邮政编码: Applicant postcode: |
46000 |
研究负责人邮政编码: Study leader's postcode: |
46000 |
|
申请人所在单位: |
伊拉克苏莱曼尼大学 |
||
|
Applicant's institution: |
Kscien Organization for Scientific Research |
||
|
研究负责人所在单位: |
伊拉克苏莱曼尼大学 |
||
|
Affiliation of the Leader: |
Sulaimani University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
125 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
伊拉克苏莱曼尼大学 |
||
|
Name of the ethic committee: |
University of Sulaimani |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-01-01 00:00:00 | ||
|
伦理委员会联系人: |
Hawbash Mohammed Amin |
||
|
Contact Name of the ethic committee: |
Hawbash Mohammed Amin |
||
|
伦理委员会联系地址: |
Mala Dawd |
||
|
Contact Address of the ethic committee: |
Mala Dawd |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+96 475 03282480 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
hawbash.mhamad@kscien.org |
|
研究实施负责(组长)单位: |
伊拉克苏莱曼尼大学 |
||||||||||||||||||||||
|
Primary sponsor: |
University of Sulaimani |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
François Mitterrand Street |
||||||||||||||||||||||
|
Primary sponsor's address: |
François Mitterrand Street |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
Smart health tower |
||||||||||||||||||||||
|
Source(s) of funding: |
Smart health tower |
||||||||||||||||||||||
|
研究疾病: |
新型冠状病毒肺炎(COVID-19) |
||||||||||||||||||||||
|
Target disease: |
Novel Coronavirus Pneumonia (COVID-19) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例研究 |
||||||||||||||||||||||
|
Study design: |
Case study |
||||||||||||||||||||||
|
研究目的: |
The aim of this study to present a series of cases with large vessel thrombosis due to COVID-19. |
||||||||||||||||||||||
|
Objectives of Study: |
The aim of this study to present a series of cases with large vessel thrombosis due to COVID-19. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1) Any patient without COVID-19; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Any patient without COVID-19; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-01-01 00:00:00至 To 2020-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-02-01 00:00:00 至 To 2020-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
No |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
None |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
None |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
the data collection was performed using an excel sheet, they were transferred to the Statistical Package for the Social Sciences (SPSS) software, version 22 after coding. Due to the small sample size, only descriptive analysis was calculated. |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
the data collection was performed using an excel sheet, they were transferred to the Statistical Package for the Social Sciences (SPSS) software, version 22 after coding. Due to the small sample size, only descriptive analysis was calculated. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |